Home
SCIENCE
Capability
Production
Analysis
Q&C
Regulatory Affairs
Innovation
Peptide
Oligo
PDC
Small Molecule
PRODUCTS & SERVICES
CRDMO
Peptide NCEs
Oligonucleotide NCEs
Small Molecules
Conjugates
APIs
Semaglutide
*
Tirzepatide
*
Liraglutide
*
Lanreotide Acetate
Octreotide Acetate
Cetrorelix Acetate
Desmopressin Acetate
Eptifibatide
Bivalirudin
Ziconotide
Oseltamivir Phosphate
Thymalfasin
Atosiban Acetate
Edotreotide
Difelikefalin
*
Pegcetacoplan
*
Fulvestrant
Oxytocin
Retatrutide
*
Teriparatide
Setmelanotide
*
Teduglutide
Atorvastatin Calcium
Alogliptin Benzoate
*
Sodium Picosulfate
Epalrestat
Agomelatine
Sulindac
Risdiplam
*
Dydrogesterone
Ezetimibe
Roxadustat
*
Rimegepant
*
Ubrogepant
*
Elacestrant
*
AT037
CPG 2216
AT035
CPG 2007
AT019
Vutrisiran
*
AT018
Patisiran
*
AT017
Givosiran
*
AT008
Inclisiran
*
AT003
CPG 1018
AT005
Nusinersen
*
Intermediates
CAS: 2158301-19-8
CAS: 1932212-66-2
CAS: 1107606-68-7
CAS: 1029716-44-6
CAS: 1027177-72-5
CAS: 916420-27-4
CAS: 875573-67-4
CAS: 875573-66-3
CAS: 651324-08-2
CAS: 204254-96-6
CAS: 137778-20-2
CAS: 34381-71-0
CAS: 20816-79-9
CAS: 3680-69-1
CAS: 1459-96-7
Product Pipeline
NEWS
News
Join us in CPHI Milan
Join us in CPHI US & TIDES US
Keeping up with the trend and showing international perspective - Sinopep in DCAT Week 2024 in New York, USA
Welcome to 2024 DCAT Week
Sinopep has obtained FDA First Adequate Letter for Semaglutide
Sinopep has obtained FDA First Adequate Letter for Liraglutide
Welcome to 2023 DCAT Week
Sinopep-Allsino Biopharmaceutical Co Ltd. attended the TIDES EUROPE 2022
Congratulations: Allsino Chemicals Co. Ltd was awarded the SK Pharmteco Preferred Partner
Sinopep-Allsino Biopharmaceutical Co Ltd. attended the CPHI Worldwide Frankfurt, Germany
Media
Interview with Tong Ziquan, Chairman of SINOPEP, by Shanghai Securities News
ABOUT US
Company
Careers
校园招聘
社会招聘
Contact Us